Related Experiment Video
Updated: Jun 3, 2026
07:59
A Radio-telemetric System to Monitor Cardiovascular Function in Rats with Spinal Cord Transection and Embryonic Neural Stem Cell Grafts
Published on: October 7, 2014
10.7K
Factor Xa: Thrombokinase from Paul Morawitz to J Haskell Milstone
1Department of Dermatology, Yale Medical School, 333 Cedar St, New Haven, CT, 06520-8059, USA. leonard.milstone@yale.edu.
Journal of Thrombosis and Thrombolysis
|January 23, 2021
Summary
J Haskell Milstone successfully isolated and characterized thrombokinase, now known as Factor Xa, a key enzyme in blood clotting. His work clarified the long-standing mystery of prothrombin activation, building on earlier hypotheses.
Area of Science:
- Biochemistry
- Hematology
- Enzymology
Background:
- Paul Morawitz proposed thrombokinase as the prothrombin activator in 1904.
- The identification and characterization of this enzyme remained a significant challenge in coagulation research for decades.
Purpose of the Study:
- To summarize J Haskell Milstone's pivotal work on thrombokinase.
- To provide context for the success of Milstone's research in isolating and characterizing Factor Xa.
Main Methods:
- Review of historical scientific literature.
- Analysis of J Haskell Milstone's experimental approaches and findings.
- Historical contextualization of coagulation factor research.
Main Results:
- J Haskell Milstone isolated, purified, and functionally characterized thrombokinase, now identified as Factor Xa.
- Milstone's work provided a definitive understanding of the enzyme responsible for prothrombin activation.
Conclusions:
- J Haskell Milstone's success can be attributed to specific methodological advancements and a deeper understanding of the coagulation cascade.
- His research resolved a critical gap in the knowledge of blood coagulation, validating earlier hypotheses.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.